Document Type

Journal Article

Publication Title

Alzheimer's Research and Therapy


BioMed Central Ltd


Centre of Excellence for Alzheimer’s Disease Research and Care / School of Medical and Health Sciences



Grant Number

NHMRC Number : APP1105784

Grant Link


Doecke, J. D., Ward, L., Burnham, S. C., Villemagne, V. L., Li, Q. X., Collins, S., ... AIBL Research Group (2020). Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research & Therapy, 12, Article 36.


Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods: Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results: Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic - area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion: Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials. © 2020 The Author(s).



Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.